N.M. Admin. Code § 16.19.26.14

Current through Register Vol. 35, No. 23, December 10, 2024

Section 16.19.26.14 - PRESCRIBING DANGEROUS DRUGS IN CONJUNCTION WITH POINT-OF-CARE TESTING

A.Protocol:

(1) Prescriptive authority shall be exercised solely in accordance with the written protocol for prescribing of dangerous drugs in conjunction with point-of-care testing (POCT) approved by the board.

(2) Any pharmacist exercising prescriptive authority for prescribing of dangerous drugs in conjunction with POCT must maintain a current copy of the written protocol approved by the board.

B.Education and training:

(1) The pharmacist must successfully complete a course of training, accredited by the accreditation council for pharmacy education (ACPE), for each category of POCT for which the pharmacist exercises prescriptive authority, provided by:

(a) the New Mexico pharmacists association; or

(b) a similar health authority or professional body approved by the board.

(2) Training must include study materials and instruction in the following content areas:

(a) mechanisms of action;

(b) contraindications;

(c) identifying indications for the use of protocol formulary drug therapy;

(d) patient screening, history and assessment criteria;

(e) counseling and training patient and care-giver regarding the safety, efficacy and potential adverse effects of prescribed protocol formulary dangerous drug(s);

(f) evaluating patient's medical profile for drug interactions;

(g) patient referrals;

(h) informed consent;

(i) record management;

(j) management of adverse events.

(3) Continuing education: Any pharmacist exercising prescriptive authority for POCT formulary drug therapy shall complete a minimum of 0.2 CEU of live ACPE approved formulary drug therapy related continuing education every two years, for each category of POCT for which the pharmacist exercises prescriptive authority. Such continuing education shall be in addition to requirements in 16.19.4.10 NMAC.

C.Authorized drug(s): Prescriptive authority shall be limited to those drugs in the Board-approved protocol.

D.Records:

(1) The prescribing pharmacist must generate a written or electronic prescription for any medication dispensed under the protocol.

(2) Informed consent must be documented in accordance with the approved protocol and a record of such consent maintained in the pharmacy for a period of at least three years.

E.Notification: Upon signed consent of the patient, the pharmacist shall notify the patient's designated physician or primary care provider within 15 days of dispensing.

N.M. Admin. Code § 16.19.26.14

Adopted by New Mexico Register, Volume XXVIII, Issue 10, May 30, 2017, eff. 6/9/2017, Amended by New Mexico Register, Volume XXXII, Issue 10, May 25, 2021, eff. 5/31/2021